99% Purity Pazopanib Hydrochloride Pazopanib Hcl Intermediate Pazopanib
Product Description
Product Details
| Product name |
Pazopanib |
| Appearance |
White powder |
| CAS NO. |
635702-64-6 |
| MF |
C21H23N7O2S.ClH |
| MW |
473.987 |
Pazopanib is researched and developed by a GlaxoSmithKline ,it is a novel oral vascular generation inhibitor which may interfere stubborn tumor survival and new blood vessels generation growth needed .Targeting vascular endothelial growth factor receptor (VEGFR),it works by inhibiting angiogenesis of tumor blood supply. it is suitable for advanced renal cell carcinoma ( a discovery of cancer cells in the renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC) treatment.
Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.
Application & Function
Pazopanib Indications:
1. FDA-approved for patients with advanced kidney cancer.
2. FDA-approved for patients with advanced soft tissue sarcoma (STS) who have previously received chemotherapy.
Specification
Audited Supplier 
){kind=link}
){kind=link}